TRx0014 in Patients With Mild or Moderate Alzheimer's Disease

This study has been completed.
Sponsor:
Information provided by:
TauRx Therapeutics Ltd
ClinicalTrials.gov Identifier:
NCT00515333
First received: August 10, 2007
Last updated: February 19, 2008
Last verified: February 2008
  Purpose

The primary objective of the study is to investigate the effects of oral TRx0014 at three doses (30, 60 and 100 mg tid) compared with placebo on cognitive ability in patients with mild or moderate dementia of the Alzheimer type. Cognitive ability will be measured by the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog). The primary evaluation will be made at 24 weeks.


Condition Intervention Phase
Dementia, Alzheimer Type
Drug: TRx0014
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: An Exploratory Placebo-Controlled, Dose-Ranging Study of the Effects of TRx0014 30 MG TID, 60 MG TID AND 100 MG TID in Patients With Mild or Moderate Dementia of the Alzheimer Type

Resource links provided by NLM:


Further study details as provided by TauRx Therapeutics Ltd:

Primary Outcome Measures:
  • Cognitive ability (ADAS-cog) [ Time Frame: At 24 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Behavioural and psychological symptoms (NPI) [ Time Frame: At 12 and 24 weeks ] [ Designated as safety issue: No ]
  • Global performance (ADCS-CGIC) [ Time Frame: At 12 and 24 weeks ] [ Designated as safety issue: No ]
  • Dementia severity (CDR-sb) [ Time Frame: At 12 and 24 weeks ] [ Designated as safety issue: No ]
  • Cognition (MMSE) [ Time Frame: At 12 and 24 weeks ] [ Designated as safety issue: No ]
  • Dementia caseness (Short CAMDEX) [ Time Frame: At 12 and 24 weeks ] [ Designated as safety issue: No ]
  • Cognitive function (ADAS-cog) [ Time Frame: At 6, 12, 18 and 24 weeks ] [ Designated as safety issue: No ]
  • Daily activities of living (BADLS) [ Time Frame: At 12 and 24 weeks ] [ Designated as safety issue: No ]
  • Changes in cerebral perfusion pattern (SPECT or PET) [ Time Frame: At baseline and between 24-26 weeks ] [ Designated as safety issue: No ]

Enrollment: 323
Study Start Date: August 2004
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1
Placebo: 0 milligrams; t.i.d.
Drug: Placebo
Hard capsule; 0 milligrams; t.i.d.
Active Comparator: 2
Treatment group: 30 milligrams; t.i.d.
Drug: TRx0014
Hard capsule; 30 milligrams; t.i.d.
Active Comparator: 3
Treatment group: 60 milligrams; t.i.d.
Drug: TRx0014
Hard capsule; 60 milligrams; t.i.d.
Active Comparator: 4
Treatment group: 100 milligrams; t.i.d.
Drug: TRx0014
Hard capsule, 100 milligrams, t.i.d.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient may be of either sex and must be supervised by a carer who is competent to ensure compliance with the medication and who is willing to participate in completing the various assessments.
  • Patients must be able to give written informed consent to participate in this study. Patients who lack capacity to consent may not be entered.
  • Competent carer must be available and must provide written consent to his or her own participation in the study.
  • Clinical diagnosis of dementia of the Alzheimer type determined by Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria and a diagnosis of Probable Alzheimer's Disease determined by the National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria. Information to support the diagnosis will include that derived from:

    • an abbreviated Cambridge Mental Disorders of the Elderly Examination (short CAMDEX) schedule, performed within six weeks prior to the baseline visit (Visit 0).
    • Computerised tomography (CT) or magnetic resonance imaging (MRI), with no time limit on previous scans. In centres conducting SPECT/PET scans as part of their routine practice or as part of the study these may be used to inform the NINCDS-ADRDA diagnosis.
  • Patient must have mild or moderate dementia as determined by:

    • Mini-Mental State Examination (MMSE) value at screening of between 10 and 26 inclusive.
    • Clinical Dementia Rating (CDR) at screening of Stage 1 or Stage 2.

Exclusion Criteria:

  • Patient has a known sensitivity to TRx0014, similar agents or any of the excipients used.
  • Screening blood sample shows that the patient has glucose-6-phosphate dehydrogenase deficiency.
  • Patient has known hereditary methaemoglobinaemia, has been known to have suffered an attack of acquired methaemoglobinaemia or has a blood level of methaemoglobin at screening which is above the upper limit of normal for age and laboratory.
  • Patient has significant impairment of renal, hepatic or haematological function for the age of the patient.
  • Patient is currently taking other anti-dementia drugs (e.g. memantine, cholinesterase inhibitors) or has taken these within the previous six weeks.
  • It is anticipated that there will be a definite indication for the commencement of other licensed anti-dementia drug treatment within the 24 week treatment period of the trial.
  • Patient has started taking other medication known to have an effect on mood or cognition (e.g. anticholinergics, hypnotics, sedatives, anxiolytics, neuroleptics, antidepressants, antiepileptics) within the previous six weeks; or has changed their dose of these medications within the previous six weeks.
  • Patient has started taking 'alternative therapy' for AD e.g. vitamin E, folic acid, hormone replacement therapy (HRT), ginkgo biloba within the previous six weeks; or has changed their dose of these treatments within the previous six weeks.
  • Patient is receiving warfarin or digitalis or any other medication that has a narrow margin between effective dose and toxic dose or between effective dose and ineffective dose, where the subject would be at risk if the levels were elevated or fell due to interaction with TRx0014.
  • Patients who are unlikely to comply with trial visit schedule or with trial medication.
  • Significant intercurrent illness which may compromise safety of the patient/validity of the data.
  • Females with the potential of childbearing and are not using adequate contraception or females who are breastfeeding.
  • Patients with a history of alcohol and/or drug abuse, defined as meeting DSM-IV criteria for substance dependence. This applies to alcohol and/or any illicit drug, including cannabis within the last six months.
  • Patient has participated in a clinical investigation of a medication or device within the previous three months.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00515333

Sponsors and Collaborators
TauRx Therapeutics Ltd
Investigators
Study Chair: Claude M Wischik, MBChB TauRx Therapeutics Ltd
Principal Investigator: Peter Bentham, MBChB Queen Elizabeth Psychiatric Hospital, Birmingham, United Kingdom
  More Information

No publications provided

Responsible Party: Professor Claude M. Wischik, TauRx Therapeutics Ltd
ClinicalTrials.gov Identifier: NCT00515333     History of Changes
Other Study ID Numbers: TRx-014-001
Study First Received: August 10, 2007
Last Updated: February 19, 2008
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by TauRx Therapeutics Ltd:
Alzheimer
Dementia

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders

ClinicalTrials.gov processed this record on April 17, 2014